BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Zonagen (ZONA) Effects Name Change To Repros Therapeutics Inc. (RPRX)


5/3/2006 2:42:24 PM

THE WOODLANDS, Texas--(BUSINESS WIRE)--May 2, 2006--Zonagen, Inc. (Nasdaq:ZONA - News; PCX:ZONA - News) today announced that it has effected its name change from Zonagen, Inc. to Repros Therapeutics Inc. The name change was approved by the Company's shareholders at the Company's annual meeting today, May 2, 2006. In conjunction with the name change, the Company also is changing its common stock ticker symbol on The Nasdaq Capital Market and the Pacific Exchange to "RPRX", commencing with the opening of trading on May 4, 2006. Along with the name and ticker symbol changes, the Company's common stock has a new CUSIP number, 76028H 10 0. Stockholders are not required to take any action with respect to the name change; however, any stockholder wishing to exchange a paper stock certificate for a new one bearing the new name may contact the Company's Chief Financial Officer at (281) 719-3400 for information and instructions.

Read at press release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES